Description

BSE revokes the suspension of trading in equity shares of Rekvina Laboratories Limited (Scrip Code: 526075), allowing normal trading to resume.

Summary

BSE has revoked the suspension in trading of equity shares of Rekvina Laboratories Limited (Scrip Code: 526075, ISIN: INE092O01028). The company is engaged in the pharmaceutical industry, providing quality medication at affordable prices. The company profile includes updated contact details, management information, and operational status.

Key Points

  • Trading suspension revoked for Rekvina Laboratories Limited equity shares
  • Scrip Code: 526075
  • ISIN: INE092O01028
  • Company operates in pharmaceutical industry with focus on affordable medication
  • Manufacturing facility located at GIDC Estate, Waghodia, Vadodara-391760
  • Registered office at Sampatrao Colony, Alkapuri, Vadodara-390007
  • Company is actively operational
  • Group company: Radiant Parenterals Limited
  • Listing fees paid to BSE

Management Details

  • Managing Director & Chairman: Amit Mukesh Shah (DIN: 01993211)
  • Directors: Surbhit Mukesh Shah, Dhruvalkumar Patel, Chetanbhai Patel, Ilaben Pathak, Parteek Jain, Deepak Khandelwal
  • Current Auditor: M/s. Y.M. Shah & Co. (FRN: 114124W) for 2024-25 to 2028-29
  • Previous Auditor: M/s. Jigar Adhyaru & Co. (2019-20 to 2023-24)
  • Auditor change was due to completion of statutory term

Regulatory Changes

None specified. This circular represents a revocation of previous trading suspension rather than introduction of new regulatory requirements.

Compliance Requirements

  • Company has fulfilled listing compliance requirements
  • Listing fees have been paid to BSE
  • No actions taken against the company by other exchanges in the last five years
  • No change in main line of business or company name in the last five years

Important Dates

  • Circular Date: December 30, 2025
  • No specific effective dates mentioned for the revocation

Impact Assessment

Market Impact: Medium - The revocation enables trading to resume, restoring liquidity for existing shareholders and allowing new market participants to trade the stock.

Operational Impact: Positive for the company as it can now access capital markets normally and shareholders can trade freely.

Investor Impact: Shareholders who were unable to exit positions during suspension can now trade their holdings. Potential investors can now participate in the stock.

Impact Justification

Revocation of trading suspension allows resumed trading activity for the company's equity shares, directly impacting shareholders and market participants.